{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:47:42Z","timestamp":1793040462340,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01ZX1905A"],"award-info":[{"award-number":["01ZX1905A"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006603","name":"BMBF","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006603","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.ejca.2022.08.029","type":"journal-article","created":{"date-parts":[[2022,10,2]],"date-time":"2022-10-02T05:15:38Z","timestamp":1664687738000},"page":"88-99","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":79,"special_numbering":"C","title":["Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life"],"prefix":"10.1016","volume":"176","author":[{"given":"Thomas U.","family":"Schulz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Zierold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Sachse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Pesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Tomsitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8667-0296","authenticated-orcid":false,"given":"Katharina","family":"Schilbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9953-0893","authenticated-orcid":false,"given":"Katharina C.","family":"K\u00e4hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lars E.","family":"French","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Heinzerling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2022.08.029_bib1","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.intimp.2018.06.001","article-title":"Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors","volume":"62","author":"Hargadon","year":"2018","journal-title":"Int Immunopharmacol"},{"issue":"10336","key":"10.1016\/j.ejca.2022.08.029_bib2","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","article-title":"Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial","volume":"399","author":"Luke","year":"2022","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.ejca.2022.08.029_bib3","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejca.2022.08.029_bib4","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.ejca.2022.08.029_bib5","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical Practice Guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2022.08.029_bib6","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: a pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2017","journal-title":"J Clin\u00a0Oncol"},{"key":"10.1016\/j.ejca.2022.08.029_bib7","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2022.08.029_bib8","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2018.09.033","article-title":"Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors","volume":"106","author":"Moreira","year":"2019","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2022.08.029_bib9","doi-asserted-by":"crossref","first-page":"fcab220","DOI":"10.1093\/braincomms\/fcab220","article-title":"Neurological complications induced by\u00a0immune checkpoint inhibitors: a comprehensive descriptive case-series unravelling high risk of long-term sequelae","volume":"3","author":"Pla\u00e7ais","year":"2021","journal-title":"Brain\u00a0Commun"},{"key":"10.1016\/j.ejca.2022.08.029_bib10","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejca.2021.03.010","article-title":"Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: an overlooked aspect in immunotherapy","volume":"149","author":"Ghisoni","year":"2021","journal-title":"Eur J Cancer"},{"issue":"5","key":"10.1016\/j.ejca.2022.08.029_bib11","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1001\/jamaoncol.2021.0051","article-title":"Chronic immune-related adverse events following adjuvant anti\u2013PD-1 therapy for high-risk resected melanoma","volume":"7","author":"Patrinely","year":"2021","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.ejca.2022.08.029_bib12","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/0284186X.2020.1818823","article-title":"Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls","volume":"60","author":"Boekhout","year":"2021","journal-title":"Acta Oncol"},{"issue":"4","key":"10.1016\/j.ejca.2022.08.029_bib13","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s11764-019-00770-0","article-title":"The survivorship experience for patients with metastatic melanoma on immune checkpoint and BRAF-MEK inhibitors","volume":"13","author":"Lai-Kwon","year":"2019","journal-title":"J Cancer Surviv"},{"issue":"2","key":"10.1016\/j.ejca.2022.08.029_bib14","first-page":"561","article-title":"An immunotherapy survivor population: health-related quality\u00a0of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors","volume":"28","author":"O'Reilly","year":"2020","journal-title":"Support Care Cancer"},{"issue":"7","key":"10.1016\/j.ejca.2022.08.029_bib15","first-page":"3267","article-title":"Health-related quality of life, emotional burden, and neurocognitive function in the first generation of metastatic melanoma survivors treated with pembrolizumab: a longitudinal pilot study","volume":"28","author":"Rogiers","year":"2020","journal-title":"Support Care Cancer"},{"issue":"1","key":"10.1016\/j.ejca.2022.08.029_bib16","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000260","article-title":"Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors","volume":"8","author":"Mamoor","year":"2020","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.ejca.2022.08.029_bib17","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ejca.2020.05.005","article-title":"Survivorship in immune therapy: assessing toxicities, body composition and health-related quality of life among long-term survivors treated with antibodies to programmed death-1 receptor and its ligand","volume":"135","author":"Patrinely","year":"2020","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.ejca.2022.08.029_bib18","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.1007\/s11136-011-9903-x","article-title":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)","volume":"20","author":"Herdman","year":"2011","journal-title":"Qual Life Res"},{"issue":"6","key":"10.1016\/j.ejca.2022.08.029_bib19","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s40273-018-0615-8","article-title":"German value set for the EQ-5D-5L","volume":"36","author":"Ludwig","year":"2018","journal-title":"Pharmacoeconomics"},{"issue":"5","key":"10.1016\/j.ejca.2022.08.029_bib20","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3109\/07853890109002087","article-title":"EQ-5D: a measure of health status from the EuroQol Group","volume":"33","author":"Rabin","year":"2001","journal-title":"Ann Med"},{"key":"10.1016\/j.ejca.2022.08.029_bib21","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/1477-7525-6-94","article-title":"Correspondence between EQ-5D health state classifications and EQ VAS scores","volume":"6","author":"Whynes","year":"2008","journal-title":"Health Qual Life Outcomes"},{"key":"10.1016\/j.ejca.2022.08.029_bib22","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1477-7525-5-70","article-title":"Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer","volume":"5","author":"Pickard","year":"2007","journal-title":"Health Qual\u00a0Life Outcomes"},{"issue":"7","key":"10.1016\/j.ejca.2022.08.029_bib23","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1136\/oem.2002.001115","article-title":"Regression modelling and other methods to control confounding","volume":"62","author":"McNamee","year":"2005","journal-title":"Occup Environ Med"},{"issue":"6","key":"10.1016\/j.ejca.2022.08.029_bib24","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1007\/s10198-019-01054-1","article-title":"Health-related quality of life measured with the EQ-5D-5L: estimation of normative index values based on a representative German population sample and value set","volume":"20","author":"Grochtdreis","year":"2019","journal-title":"Eur J Health Econ"},{"issue":"4","key":"10.1016\/j.ejca.2022.08.029_bib25","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"10.1016\/j.ejca.2022.08.029_bib26","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.annonc.2021.03.204","article-title":"Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma","volume":"32","author":"Owen","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2022.08.029_bib27","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejca.2019.01.015","article-title":"Adverse events 2.0\u2014let us get SERIOs: new reporting for adverse event outcomes needed in the era of immunooncology","volume":"112","author":"Heinzerling","year":"2019","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.ejca.2022.08.029_bib28","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/pon.956","article-title":"How do patients who participate in cancer support groups differ from those who do not?","volume":"15","author":"Grande","year":"2006","journal-title":"Psychooncology"},{"issue":"10","key":"10.1016\/j.ejca.2022.08.029_bib29","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1002\/pon.1317","article-title":"Socio-demographic, psychosocial and attitudinal predictors of help seeking after cancer diagnosis","volume":"17","author":"Steginga","year":"2008","journal-title":"Psychooncology"},{"issue":"4","key":"10.1016\/j.ejca.2022.08.029_bib30","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1001\/jamaoncol.2019.5570","article-title":"Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive pembrolizumab or placebo: a secondary analysis of a randomized clinical trial","volume":"6","author":"Eggermont","year":"2020","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.ejca.2022.08.029_bib31","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/0277-9536(91)90156-7","article-title":"Underreporting by cancer patients: the case of response-shift","volume":"32","author":"Breetvelt","year":"1991","journal-title":"Soc Sci Med"},{"issue":"8","key":"10.1016\/j.ejca.2022.08.029_bib32","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant pembrolizumab after nephrectomy in renal-cell carcinoma","volume":"385","author":"Choueiri","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2022.08.029_bib33","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ejca.2020.03.016","article-title":"Adjuvant immunotherapy: the sting in the tail","volume":"132","author":"Higham","year":"2020","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.ejca.2022.08.029_bib34","first-page":"271","article-title":"Immune checkpoint inhibitor therapy","volume":"23","author":"Wood","year":"2019","journal-title":"Clin J Oncol Nurs"},{"issue":"36","key":"10.1016\/j.ejca.2022.08.029_bib35","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"}],"updated-by":[{"DOI":"10.1016\/j.ejca.2025.115236","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,2,25]],"date-time":"2025-02-25T00:00:00Z","timestamp":1740441600000}}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922005226?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804922005226?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:37:59Z","timestamp":1760733479000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804922005226"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":35,"alternative-id":["S0959804922005226"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2022.08.029","relation":{"erratum":[{"id-type":"doi","id":"10.1016\/j.ejca.2025.115236","asserted-by":"object"}]},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients' health-related quality of life","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2022.08.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}